Circulating visfatin levels in healthy preterm infants are independently associated with high-density lipoprotein cholesterol levels and dietary long-chain polyunsaturated fatty acids.
The adipokine visfatin has been proposed to exert insulin-mimicking effects and to play a role in the development of metabolic syndrome. Preterm infants are at risk for the later development of insulin resistance and, possibly, for other components of metabolic syndrome. Dietary long-chain polyunsaturated fatty acids (LCPUFAs) during the perinatal period may reduce the risk of metabolic syndrome. The authors' objective was to study the circulating concentrations of visfatin in preterm infants and to examine associations of visfatin with anthropometric measurements, metabolic indices, and dietary LCPUFAs. Serum visfatin concentrations were determined by enzyme-linked immunosorbent assay at mean (SD) 33.8 (11.7) days of life in 60 healthy preterm infants (gestational age, 32.7 [1.9] weeks) randomly assigned to be fed since birth either a formula containing LCPUFA (arachidonic and docosahexaenoic acid) (+LCPUFA group) or the same formula without LCPUFA (-LCPUFA group). Associations of visfatin with anthropometric parameters, serum glucose, insulin, homeostasis model assessment index of insulin resistance, blood lipids, and adiponectin levels were examined. Serum visfatin levels were significantly higher in the +LCPUFA than in the -LCPUFA group (P < .001) and correlated positively with body weight z score (β = 0.31, P = .02), total cholesterol (β = 0.34, P = .01), high-density lipoprotein cholesterol (HDL-C) (β = 0.47, P < .001), and adiponectin levels (β = 0.29, P = .03), but not with indices of insulin sensitivity. In multiple regression analysis, HDL-C and dietary LCPUFAs correlated independently with serum visfatin levels. Circulating visfatin levels in preterm infants are independently associated with HDL-C levels and dietary LCPUFAs. Whether the higher visfatin levels in the +LCPUFA preterm infant group are beneficial for the later health of these infants remains to be determined.
Siahanidou
Tania
T
Neonatal Unit, First Department of Pediatrics, Athens University Medical School, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece. siahan@med.uoa.gr
Margeli
Alexandra
A
Kappis
Athanasios
A
Papassotiriou
Ioannis
I
Mandyla
Helen
H
D052242:Adiponectin / Q000097:blood; D000886:Anthropometry; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000502:physiology; D008076:Cholesterol, HDL / Q000097:blood*; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D041943:Infant Formula / Q000008:administration & dosage; D007227:Infant Nutritional Physiological Phenomena; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D024821:Metabolic Syndrome / Q000517:prevention & control; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D012044:Regression Analysis; D014280:Triglycerides / Q000097:blood
D052242:Adiponectin; D001786:Blood Glucose; D008076:Cholesterol, HDL; D005231:Fatty Acids, Unsaturated; D007328:Insulin; D014280:Triglycerides; D054409:Nicotinamide Phosphoribosyltransferase